Private Trust Company’s Edwards Lifesciences EW Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $368K | Sell |
4,072
-111
| -3% | -$9.3K | 0.03% | 597 |
|
|
2026
Q1 | $335K | Buy |
4,183
+282
| +7% | +$23.2K | 0.03% | 581 |
|
|
2025
Q4 | $333K | Sell |
3,901
-107
| -3% | -$8.78K | 0.03% | 567 |
|
|
2025
Q3 | $312K | Sell |
4,008
-338
| -8% | -$26.4K | 0.03% | 579 |
|
|
2025
Q2 | $340K | Buy |
4,346
+380
| +10% | +$28.3K | 0.03% | 530 |
|
|
2025
Q1 | $287K | Buy |
3,966
+525
| +15% | +$37.6K | 0.03% | 574 |
|
|
2024
Q4 | $255K | Buy |
3,441
+510
| +17% | +$35.7K | 0.03% | 598 |
|
|
2024
Q3 | $193K | Buy |
2,931
+233
| +9% | +$16.9K | 0.02% | 712 |
|
|
2024
Q2 | $249K | Buy |
2,698
+101
| +4% | +$8.94K | 0.03% | 583 |
|
|
2024
Q1 | $248K | Sell |
2,597
-14
| -0.5% | -$1.18K | 0.03% | 567 |
|
|
2023
Q4 | $199K | Sell |
2,611
-147
| -5% | -$10.2K | 0.02% | 617 |
|
|
2023
Q3 | $191K | Sell |
2,758
-8,652
| -76% | -$695K | 0.03% | 588 |
|
|
2023
Q2 | $1.08M | Buy |
11,410
+125
| +1% | +$10.9K | 0.14% | 175 |
|
|
2023
Q1 | $934K | Buy |
11,285
+7
| +0.1% | +$550 | 0.13% | 195 |
|
|
2022
Q4 | $841K | Sell |
11,278
-9
| -0.1% | -$694 | 0.12% | 204 |
|
|
2022
Q3 | $933K | Sell |
11,287
-190
| -2% | -$18.3K | 0.15% | 156 |
|
|
2022
Q2 | $1.09M | Sell |
11,477
-3,230
| -22% | -$334K | 0.17% | 147 |
|
|
2022
Q1 | $1.73M | Buy |
14,707
+3,028
| +26% | +$340K | 0.27% | 100 |
|
|
2021
Q4 | $1.51M | Sell |
11,679
-1,150
| -9% | -$134K | 0.21% | 125 |
|
|
2021
Q3 | $1.45M | Buy |
12,829
+8,862
| +223% | +$1.01M | 0.21% | 122 |
|
|
2021
Q2 | $411K | Hold |
3,967
| – | – | 0.06% | 289 |
|
|
2021
Q1 | $331K | Buy |
3,967
+213
| +6% | +$18K | 0.05% | 319 |
|
|
2020
Q4 | $342K | Sell |
3,754
-463
| -11% | -$38.4K | 0.06% | 289 |
|
|
2020
Q3 | $336K | Buy |
4,217
+821
| +24% | +$64.1K | 0.06% | 279 |
|
|
2020
Q2 | $234K | Buy |
3,396
+138
| +4% | +$9.81K | 0.05% | 319 |
|
|
2020
Q1 | $204K | Sell |
3,258
-174
| -5% | -$12.5K | 0.05% | 321 |
|
|
2019
Q4 | $266K | Buy |
3,432
+3
| +0.1% | +$234 | 0.05% | 326 |
|
|
2019
Q3 | $251K | Hold |
3,429
| – | – | 0.05% | 321 |
|
|
2019
Q2 | $211K | Sell |
3,429
-9,258
| -73% | -$560K | 0.04% | 351 |
|
|
2019
Q1 | $809K | Sell |
12,687
-2,451
| -16% | -$140K | 0.17% | 146 |
|
|
2018
Q4 | $772K | Buy |
15,138
+309
| +2% | +$15.6K | 0.18% | 138 |
|
|
2018
Q3 | $860K | Sell |
14,829
-132
| -0.9% | -$6.46K | 0.18% | 145 |
|
|
2018
Q2 | $725K | Sell |
14,961
-1,188
| -7% | -$55.5K | 0.16% | 159 |
|
|
2018
Q1 | $751K | Buy |
+16,149
| New | +$701K | 0.16% | 158 |
|
|
2014
Q4 | – | Sell |
-2,580
| Closed | -$44K | – | 570 |
|
|
2014
Q3 | $44K | Hold |
2,580
| – | – | 0.01% | 586 |
|
|
2014
Q2 | $37K | Sell |
2,580
-84
| -3% | -$1.14K | 0.01% | 651 |
|
|
2014
Q1 | $33K | Sell |
2,664
-1,302
| -33% | -$15K | 0.01% | 602 |
|
|
2013
Q4 | $43K | Buy |
3,966
+858
| +28% | +$9.67K | 0.02% | 480 |
|
|
2013
Q3 | $36K | Buy |
3,108
+474
| +18% | +$5.54K | 0.02% | 498 |
|
|
2013
Q2 | $30K | Buy |
+2,634
| New | +$31.2K | 0.01% | 512 |
|
Other funds holding EW
Private Trust Company's EW Position: Q2 2026 in Review
Private Trust Company reduced its Edwards Lifesciences (EW) stake by 2.7% in Q2 2026, selling an estimated $9.3K and leaving 4,072 shares worth $368K. The position accounts for 0.03% of the portfolio, ranked #597.
Private Trust Company first reported a position in EW in Q2 2013 and has held it in 40 quarters since. The position peaked at $1.73M in Q1 2022. 1,327 funds tracked by Wall St. Rank hold EW as of Q2 2026.
- Private Trust Company held 4,072 shares of Edwards Lifesciences worth $368K as of Q2 2026.
- Private Trust Company sold 111 Edwards Lifesciences shares in Q2 2026, an estimated $9.3K.
- Edwards Lifesciences made up 0.03% of Private Trust Company's portfolio in Q2 2026, its #597 holding.
- Private Trust Company first reported a position in Edwards Lifesciences in Q2 2013 and has held it in 40 quarters since.
- Private Trust Company's Edwards Lifesciences position peaked at $1.73M in Q1 2022.
- 1,327 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q2 2026.
Based on Private Trust Company's 13F filing for Q2 2026, filed 28 Jul 2026.